Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Takeda Pharmaceutical has submitted an application to the Ministry of Health, Labour and Welfare in Japan for an additional indication of Basen tablets 0.2 and Basen OD tablets 0.2 for prevention of onset of type 2 diabetes in patients with impaired glucose tolerance.
Subscribe to our email newsletter
Basen was launched in 1994 in Japan as an improving agent for postprandial hyperglycemia in diabetes mellitus, with its mechanism of action of delaying the digestion and absorption of carbohydrate, resulting in improvement of postprandial hyperglycemia.
Masaomi Miyamoto, general manager of pharmaceutical development division of Takeda, said: “Once this application is approved, we will be able to offer a new treatment option of medicinal therapy for patients with IGT and healthcare providers who treat them.”